Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development
PR Newswire•23/10/2026•21:26 ET
10
Key Highlights
- ➤Lunit and Summit agree to apply SCOPE IO in ivonescimab development
- ➤AI analysis will evaluate H&E slides for tumor microenvironment features
- ➤Research may support biomarker discovery and patient selection strategies
- ➤No clinical outcome data are announced in this agreement
- ➤Ivonescimab remains investigational in Summit’s license territories
Expert Statements
Allen Yang, Chief Research and Development Strategy Officer of Summit
“Understanding the tumor microenvironment is increasingly important as immuno-oncology moves beyond single-axis checkpoint inhibition toward more complex mechanisms and combinations,”
Allen Yang, Chief Research and Development Strategy Officer of Summit
“We are pleased to work with Lunit to explore how AI-powered pathology can help generate deeper, more scalable insights from routine tissue samples and inform the continued development of ivonescimab.”
Brandon Suh, CEO of Lunit
“Summit is at the forefront of next-generation immuno-oncology development, and we are excited to support its efforts with Lunit SCOPE IO,”
Brandon Suh, CEO of Lunit
“By extracting quantitative, spatially resolved immune and tumor microenvironment features from standard H&E slides, we believe SCOPE IO can help biopharma partners better understand which patients may benefit from immuno-oncology therapies and why.”
Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development PR Newswire
Research Will Use Lunit's AI-powered Pathology Platform to Analyze H&E Whole-Slide Images and Generate Scalable Insights into Tumor Microenvironment Biology
Get started
Create a free account to read the full story.